CONMED Corporation (CNMD) stock analysis
Healthcare · Medical Devices
From the 10-K filed 2026-02-17
Business type: Franchise
How it makes money
Conmed earns revenue by selling surgical devices across two main lines, with single-use items driving recurring sales.
Conmed provides devices and equipment for surgical procedures used by surgeons and other healthcare professionals in specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Its operations are divided into two main product lines: orthopedic surgery and general surgery. Orthopedic surgery generated 42% of consolidated net sales in 2025, 42% in 2024, and 43% in 2023. General surgery accounted for 58% of consolidated net sales in 2025, 58% in 2024, and 57% in 2023.
Approximately 86% of revenues are derived from the sale of single-use products used in surgical procedures. Capital equipment offerings facilitate the ongoing sale of related single-use products and accessories, which provides the company with a recurring revenue stream. Additionally, approximately 14% of 2025 revenues were derived from the sale of capital products, the sales of which may be negatively impacted if hospitals and other healthcare providers are unable to secure financing or defer purchases. International sales represented approximately 44% in 2025, 43% in 2024, and 44% in 2023.
What protects it: the moat
Conmed relies on quality accreditations and intellectual property protection, though it faces various litigation and regulatory compliance risks.
The company is committed to offering products with high standards of quality, technological excellence, and customer service. Substantially all of its facilities have attained certification under the International Organization for Standardization international quality standards and other domestic and international quality accreditations.
Management notes risks regarding the ability to defend and enforce intellectual property, including theft or compromise of intellectual property in connection with international operations. Conmed also faces risks of patent, product, and other litigation along with associated costs, alongside regulatory compliance requirements and potential enforcement actions by domestic and foreign agencies.
What growth costs
Conmed incurs costs from manufacturing, operating expenses, R&D, and capital spending, while engaging in acquisitions and portfolio optimization.
The company manufactures substantially all of its products in facilities located in the United States and Mexico. In recent years, it has experienced higher manufacturing and operating costs, ongoing supply chain challenges, and impacts from tariffs placed on imported goods and exporting products to other countries, prompting the engagement of a consulting firm in 2025 to evaluate and propose improvements in manufacturing operations.
Conmed has historically used strategic business acquisitions, internal product development, and distribution relationships to diversify product offerings, increase market share, realize economies of scale, and take advantage of growth opportunities in healthcare. Additionally, during 2025, the company performed a product portfolio review resulting in the discontinuation of certain products, the cancellation of planned new product lines, and an announced intent to exit its gastroenterology product lines.
What could damage it
Government actions restricting Ethylene Oxide sterilization capacity could prevent Conmed from selling sterile products if alternative methods are unachievable.
Approximately 31% of Conmed's products, measured in terms of 2025 revenues, are sterilized by third-party sterilizers using Ethylene Oxide. Ethylene Oxide has raised environmental concerns in certain U.S. areas, leading to temporary or permanent closures of sterilization facilities due to government enforcement actions or enhanced regulations.
If further restrictions or adverse government actions occur, Conmed may be unable to transition to other contract sterilizers or sterilization methods in a timely or cost-effective manner, which could materially impact the business and limit its ability to sell certain sterile products.
About CONMED Corporation
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as powered resection instruments, fluid management and visualization systems, and related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solutions comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures; and products to treat diseases of dilation, hemostasis, biliary, stricture management, and infection prevention, as well as ECG electrodes, EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.